Clinical Practice Guidelines for CLOVES Syndrome – Vascular Anomalies Center, Boston Children’s Hospital
Imaging Guidelines for Vascular Anomalies developed by Children’s Hospital Boston – Guidelines for imaging with MRI, ultrasound, CT and angiogram when indicated.
Recommended Kidney Screening for children with CLOVES – Recommended screening guidelines for children with CLOVES, developed February 2012
The Vascular Anomalies Center team at Children’s Hospital Boston recently became aware of three cases of Wilms Tumor in young patients with CLOVES syndrome. While Wilms tumor has been associated with some overgrowth related disorders, such as Beckwith-Wiedemann Syndrome, it is a new finding in patients with CLOVES syndrome.
Our recommendation for Wilms tumor screening is serial ultrasounds performed every three months up to age 8 years after which there is not thought to be any increased risk of developing Wilms tumor. We have also chosen to notify families and physicians of CLOVES syndrome patients between the ages of 8 and 12 years so that they may decide whether to obtain a single ultrasound to rule out late development of Wilms tumor.
Questions may be addressed to your child’s pediatrician or to the Vascular Anomalies Center, Children’s Hospital Boston, at 617-355-5226.
There are recent publications about Wilms Tumor in young patients with CLOVES syndrome. While Wilms tumor has been associated with some overgrowth related disorders, such as Beckwith-Wiedemann Syndrome, it is a new finding in patients with CLOVES syndrome.
Treatments & Trials
Unfortunately, there is no cure for CLOVES. Surgery and other types of medical interventions are the primary treatments for CLOVES overgrowth, vascular anomalies and other related medical issues. Please read below about research opportunities and new targeted treatment medications to treat CLOVES/PROS.
This is a prospective Phase II multi-center study with an upfront 16-week, randomized, double-blind, placebo-controlled period, and extension periods, to assess the efficacy, safety and pharmacokinetics of alpelisib in pediatric and adult participants with PIK3CA-related overgrowth spectrum (PROS). Enrollment is expected to begin in February of 2021.
The genetics of AVMs are poorly understood, and many theories currently exist with regards to their development, including the hypothesis that their development begins early in gestation. Kahle Lab is actively recruiting patients with brain or spinal cord AVMs and their families. Participants must have a formal diagnosis based on imaging. This study is currently open to people in the United States.
If you are interested in participating, please email [email protected] with the following information:
- Mailing Address or Addresses where the swabs and paperwork will be sent
- Active contact telephone number
- Full Names and Ages of participants at each address that will provide DNA samples in your household
- Previously referred to genetics? If so, findings?
8/28/20 – VT30-101 is a 2-part first-in-human trial of topically administered VT30 to subjects with cutaneous venous malformations, lymphatic malformations, or mixed venolymphatic malformations associated with PIK3CA or TEK mutations.
Part 1 is a 4-week treatment, open-label, 4-sequence, escalating repeat-application cohort study, with intra-subject and inter-cohort dose escalation.
Part 2 is a 12-week treatment, randomized, placebo-controlled, double-blind, safety and exploratory efficacy study. Part 2 will be initiated only after the successful completion of Part 1 with results that demonstrate the general safety and tolerability of topically applied VT30. Up to 12 subjects who complete Part 1 may be enrolled into Part 2 of the study.
The primary objective is to evaluate the safety and tolerability of VT30. The study will also determine the dose and regimen of VT30 to be carried into Part 2 of the protocol. Other aims include documenting plasma drug levels of VT30 and VT10 and, on an exploratory basis, examining pharmacologic target engagement and change in potential efficacy readouts.
Compassionate Use Access of PIQRAY (formerly BYL719/alpelisib) [7-9-19]
The Novartis Managed Access Program (MAP) for PIQRAY use in PROS is available to patients in the US where PIQRAY is available for commercial use (as well as other countries where not approved).
The FDA approved PIQRAY for HR+/HER2- advanced breast cancer, and thus PROS patients may seek access to the medication through MAP.
Patients should contact their treating physicians who can, if clinically appropriate, make a request to Novartis for access to treatment using this link on the Novartis website https://www.novartis.com/our-focus/healthcare-professionals/managed-access-programs
New Research Opportunity: MOSAIC – ARQULE [6-5-19]
ArQule is currently conducting the MOSAIC (Miransertib in Overgrowth Syndromes in Adults and Children) clinical trial for patients who have been diagnosed with either Proteus syndrome (PS), which involves a mutation in the AKT gene, or those who have been diagnosed with one of a number of distinct overgrowth disorders characterized by a mutation in the PIK3CA gene, referred to as PIK3CA-related overgrowth spectrum (PROS). There are currently no approved medicinal treatments for PS and PROS, leaving patients with minimal treatment options. ArQule was purchased by Merck in January of 2020.
The MOSAIC trial aims to determine whether miransertib, a drug which inhibits the biological pathway that both AKT and PIK3CA mutations affect, can effectively treat patients who are diagnosed with overgrowth syndromes associated with these mutations.
Based on the mechanism of action of miransertib, trial participants must have a mutation in either the AKT1 or PIK3CA gene to be eligible to participate in the MOSAIC trial. Learn more about how miransertib works below.
- For more information, please visit the Clinical Trial page
- Additional information about the MOSAIC trial can be found here.
New Research Opportunity: BYL719/NOVARTIS [6-13-18]
A medical first: CLOVES Syndrome and overgrowth syndromes:remarkable improvement in the health of 19 pediatric and adult patients using a new therapeutic strategy called Alpelisib BYL719. Dr. Guillaume Canaud at the Necker-Enfants Malades Hospital – AP-HP, the Paris Descartes University, Inserm (INEM Institute Necker Enfants Malades – Centre for Molecular Medicine) and his team recently demonstrated the efficacy of a novel medication, a specific inhibitor called BYL719, in a cohort of 19 patients treated at the Necker-Enfants Malades Hospital – AP-HP and suffering from CLOVES Syndrome (Congenital Lipomatous Overgrowth, Vascular Malformation, Epidermal Naevi) or similar disorders.
Opportunity for CLOVES Research (ongoing)
April 23, 2013 – Research Opportunity with National Institutes of Health (NIH)
CLOVES syndrome is different than most other genetic conditions in that it is not inherited. The gene changes that cause CLOVES syndrome in a person are not found in that person’s parents, siblings, or children. CLOVES syndrome is caused by changes (“mutations”) in a gene called PIK3CA and these changes are only present in some of a person’s cells. Just like people with CLOVES syndrome have some affected parts of their bodies and some unaffected parts of their bodies (for example, differences in just one leg but not the other, or skin changes in some places and not others), the PIK3CA mutations that cause CLOVES syndrome in a person are not present in all of that person’s cells. Scientists use different words to describe this, including “mosaicism,” and “segmental.” No matter what term is used, the important thing to know about CLOVES syndrome is that where and how you look for a causative mutation really matters. This graphic describes the genetics of CLOVES syndrome.
Genetic testing can be very helpful for people with CLOVES syndrome. Having a genetic test can help families and doctors understand treatment options that are already available. Treatments that are currently being tested or may become available in the future may also rely on a person’s genetic test results. Many healthcare providers are still unfamiliar with what mutations to test for and what samples are needed. Approximately half of the families involved in the CLOVES syndrome community have told us they had difficulty with genetic testing. The most common challenges are insurance coverage and getting the right kind of genetic test.
Genetic testing for CLOVES syndrome/PROS is more complicated than other kinds of genetic testing. It is important to be sure that the right sample is sent for testing and to understand how different genetic testing laboratories perform the test. You can read more about this in our FAQ. This site also has a good explanation of genetic testing.
What sample will be used for testing?
Almost all traditional genetic testing is done using blood or saliva samples. These are NOT the best samples to use for genetic testing for CLOVES syndrome. PIK3CA mutations that cause CLOVES syndrome just can’t be detected as well (or at all) in DNA that comes from these types of samples. No genetic test is perfect, but if a mutation is there, choosing a sample that comes from a part of the body that is clearly “affected” (showing signs of CLOVES syndrome) has the highest chance of finding it. For most people, this means having a skin biopsy done. Another option is to use tissue that might be available from a surgery that would ordinarily be thrown away. Having a skin biopsy (or sending surgical samples for genetic testing) takes more work for families and clinicians, and many parents don’t like the idea of having their child have a biopsy. Because genetic testing can be expensive and difficult to arrange, it’s often worth it to make sure that the best possible sample is used.
What laboratory will do the test?
Not all genetic testing laboratories (and there are LOTS of genetic testing labs!) test for CLOVES syndrome. Most offer CLOVES syndrome genetic testing as part of a “panel.” Many different genes that may cause similar conditions are tested at the same time. In some cases, the lab will only test specific mutations within the PIK3CA gene. Sometimes a person’s insurance will cover genetic testing at some laboratories and not others. It’s important for you and your doctor to understand the specific test that will be done. Exome sequencing, a very comprehensive and increasingly common test, especially for people with rare conditions, may not be the best test for people with CLOVES syndrome. It is very expensive and is often only done using a blood sample. Many families tell us that they had exome sequencing as their first diagnostic test. While CLOVES Syndrome Community does not endorse any of the following laboratories, they each offer tests that, when performed on the right DNA source or tissue sample, have a higher chance of finding a PIK3CA gene change compared to others.
When considering genetic testing, here are some “green lights” and “red flags” that can help you and your doctor decide on the best test for you/your child:
|Test||Green lights – signs of a more appropriate test for CLOVES syndrome||Red flags – signs of a less appropriate test for CLOVES syndrome|
|Sample type||fresh tissue, frozen tissue, DNA extracted from tissue||blood, saliva, DNA extracted from blood or saliva|
|Name of test||“Somatic overgrowth panel” includes “CLOVES syndrome” or “mosaic overgrowth” in name of test||Name of test seems to test for something else, e.g., “polydactyly panel”|
|Coverage||“deep sequencing” “ultra deep sequencing” “100x” “250x”||“20x coverage”|
|Detection language||“limit is 1%” “limit is 5%”||“variants present at <20% may not be reliably detected”|
How will the test be done?
There are lots of different ways genetic tests can be done. Finding the responsible mutation in a person with CLOVES syndrome is more of a “needle in a haystack” situation than many genetic tests because even in the “perfect” sample, the percentage of DNA with the mutation is lower than with other genetic conditions. Genetic tests designed to find the low-frequency mosaic mutations common in CLOVES syndrome are the best ones for people with CLOVES syndrome to get. It can be important to understand what the test’s lowest frequency is. Can the test find a mutation that may only be present in 1% of the DNA from the sample? 5%? 25%? Also, some genetic tests just look for specific mutations in specific genes, while others read through (“sequence”) whole genes. Having this information in advance can help families and providers pick the best test for the situation.
What will the results mean?
A “positive” result means that the test found a gene change or mutation in a gene that is known to be associated with CLOVES syndrome. Most people with CLOVES syndrome who get positive test results will have changes in the PIK3CA gene. A “negative” result can be complicated in a condition like CLOVES syndrome for a couple of reasons:
1) No genetic test is 100% perfect
2) A mutation may be present but not at a high enough level for the test to find. The lab may label any mutations found in less than 5% of the DNA in the sample as “negative.”
3) A mutation may not be present because the sample came from blood or saliva. This is common in CLOVES syndrome and why we suggest that DNA from biopsies is the best sample to send for genetic testing
4) A “true negative:” we do not know 100% of the genes that cause CLOVES syndrome so even a perfect test from a perfect sample will not give a positive result in a person whose mutation in a gene that has not been discovered yet.
Additional Resources for Genetics:
Visual created by the National Institutes of Health to help explain PIK3ca mutations and overgrowth. [March 20, 2017]
NIH Ongoing Research for PIK3CA mutations:
The National Institutes of Health does research testing of patients with all kinds of overgrowth. If you’d like to learn more, contact them at [email protected] or by phone at 301-435-6689. More information can be found here https://www.ncbi.nlm.nih.gov/gtr/tests/5534/
CLOVES Genetic Mutation Discovery (5/31/12)
Researchers at Boston Children’s Hospital identify a genetic cause for CLOVES
CLOVES Syndrome is an overgrowth syndrome with complex vascular anomalies. CLOVES stands for Congenital, Lipomatous Overgrowth, Vascular malformations, Epidermal nevi and Scoliosis/Skeletal/Spinal anomalies. The syndrome was described independently by Saap et al. and Alomari [1,2]. The syndrome shows no inheritance among families of affected patients.
CLOVES syndrome is rare and very variable; ranging from mild to severe. The common features in most patients allow for proper diagnosis and distinction from other syndromes. The most consistent features of the syndrome are:
- Fatty Truncal Mass: Typically, a soft fatty mass of variable size is noted at birth. The mass can be seen in one or both sides of the back and abdominal wall and extending into gluteal or groin regions. The skin over the mass is covered with a red-pinkish birthmark known as a port-wine stain or capillary malformation. The fatty mass may extend into the chest, abdomen or into the spinal canal (around the spinal cord).
- Vascular Anomalies: In addition to the skin birthmark, patients with CLOVES syndrome have abnormal lymphatic and venous channels. In addition, a group of patients suffer from a more aggressive vascular anomaly (Arteriovenous malformation – AVM) around the area of the spinal cord.
- Abnormal extremities (arms and legs) and scoliosis (curving of the spine) are common. A person with CLOVES may have large wide hands or feet, large fingers or toes, wide space between digits and uneven size of extremities.
- Skin abnormalities include birthmarks, prominent veins, lymphatic vesicles, moles and epidermal nevus (light brownish slightly raised skin in the upper chest, neck or face).
- Other abnormalities include small or absent kidney, abnormal patella (knee cap), knee and hip joints.
Most people with CLOVES syndrome do not have all these signs, but rather a combination of abnormalities; though some can be subtle or deeply seated and requires a dedicated physical exam and proper imaging studies.
The diagnosis can be established right after birth, though prenatal diagnosis with modern imaging tools may be feasible .
Historically CLOVES Syndrome diagnosis has been made by medical exam, observed physical characteristics and clinical information/history. With the discovery of genetic mutation in CLOVES and PROS conditions, tissue testing for PIK3CA can be performed. The diagnosis can be established right after birth, though prenatal diagnosis with modern imaging tools may be feasible.
- Fatty Truncal Mass
- Vascular Anomalies
- Abnormal extremities
- Skin abnormalities
- Other abnormalities include small or absent kidney, abnormal, knee and hip joints, and/or scoliosis.
The management of CLOVES syndrome can be very challenging and requires an interdisciplinary team of physicians with experience in overgrowth and vascular anomalies.
- Sapp JC, Turner JT, van de Kamp JM, van Dijk FS, Lowry RB, Biesecker LG. 2007. Newly delineated syndrome of congenital lipomatous overgrowth, vascular malformations, and epidermal nevi (CLOVE syndrome) in seven patients. AmJ Med Genet Part A 143A: 2944-2958.
- Alomari AI. 2009. Characterization of a distinct syndrome that associates complex truncal overgrowth, vascular, and acral anomalies: A descriptive study of 18 cases of CLOVES syndrome. Clin Dysmorphol;18:1-7.
- Fernandez-Pineda I, Fajardo M, Chaudry G, Alomari AI. Perinatal clinical and imaging features of CLOVES syndrome. Pediatr Radiol.
Working with Industry
CLOVES Syndrome Community seeks the highest level of ethical conduct in engagement with biopharmaceutical companies. The goal of engaging with biopharmaceutical companies is to help enable the development of therapies while maintaining our autonomy.
Guidelines for Interactions Between CLOVES Syndrome Community and Biopharmaceutical Companies
The interactions between CLOVES Syndrome Community (“CSC”) and biopharmaceutical companies are important and complex. Collaborations between these two stakeholders have become more common in recent years as CLOVES Syndrome Community has evolved and biopharmaceutical industry activity has increased, particularly in rare diseases.
The principles outlined in the following guidelines are intended to help CLOVES Syndrome Community navigate critically important interactions with biopharmaceutical companies.
These guidelines were developed with input from an Independent Expert Panel from the rare disease community with expertise in these collaborations from both the industry and patient advocacy organization point of view. More information on the Independent Expert Panel and the process for developing these Guidelines is provided in the article entitled “Principles for interactions with biopharmaceutical companies: the development of guidelines for patient advocacy organizations in the field of rare diseases,” published in The Orphanet Journal of Rare Diseases, 2018.
CLOVES Syndrome Community seeks the highest level of ethical conduct in engagement with biopharmaceutical companies. The goal of engaging with biopharmaceutical companies is to help enable the development of therapies while maintaining our autonomy. All interactions between CLOVES Syndrome Community, industry and the disease community should be transparent; should enable trust, accountability and shared learning; and ultimately should work most efficiently and effectively toward advancing meaningful treatments for patients.
There are four main areas of engagement between CLOVES Syndrome Community and biopharmaceutical companies described in the following Guidelines:
- Identification and Engagement with Companies
- Patient Engagement and Patient Privacy
- Financial Contributions
- Clinical Trial Communication and Support
Patient Support & Emotional Wellbeing
Patient-centered care is key to obtaining positive health outcomes. Studies have shown it is vital to treat the whole patient and not just the disorder. We strongly suggest you refer all families affected by CLOVES to our site. Here they can learn more about CLOVES, join our registry, obtain information on a number of resources, and find support by joining our community.
PIK3CA Related Conditions Research Network
CLOVES Syndrome Community is proud to be launching the PIK3CA Related Conditions Collaborative Research Network, a patient and caregiver led research network that encourages the sharing of ideas among patients, scientists, and physicians. CLOVES Syndrome Community is one of thirty organizations chosen to participate in the Rare As One Network, which will provide CSC with capacity building tools, resources, funding, training and support, to strengthen our expanding patient community and scientific goals.
CLOVES Syndrome Community is working to create a patient-led collaborative research network in order to broaden the medical knowledge base, accelerate treatment options and improve quality of life for people with CLOVES and PIK3CA Related Conditions.
A patient led collaborative research network pulls together a community of stakeholders – including people with specific diseases, their family members, researchers and physicians – to discover and prioritize critical research questions. The research network relies on the collective voice to identify the most pressing questions and knowledge gaps about a disease. It then recruits the most qualified researchers to help answer these questions and to conduct these studies. We believe in the power of the collective. We believe that together, we can make a change in the lives of people with CLOVES and PIK3CA Related Conditions.
Sign up to learn more about our goals and upcoming projects.
The publications database will serve as a reference list and educational resource for our existing community as well as young researchers and clinicians as we develop our International PIK3CA Conditions Collaborative Research Network. The database contains information as well as Pubmed links to all published literature on CLOVES and more broadly, on PROS. In this resource, we highlight different article types such as primary research, case series, and reviews, as well as areas of research such as diagnosis, management, and treatment of CLOVES/PROS. New articles will be added each month as they are published to keep our community up to date.
The publications database is best viewed on a large screen such as a computer or Ipad.